The BAG5 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the LoVo human colorectal adenocarcinoma cell line. This product provides a loss-of-function model for investigating the co-chaperone BAG5, enabling targeted studies of its regulatory roles in protein quality control and cellular homeostasis. The polyclonal format offers a heterogeneous knockout pool suitable for phenotypic screening and functional assays without clonal selection bias.
LoVo cells are an adherent epithelial cell line established from a metastatic lymph node site of a 56-year-old male with colorectal adenocarcinoma. This well-characterized model retains key oncogenic features, including rapid proliferation and metastatic potential, making it a relevant platform for dissecting tumor biology. LoVo cells have been widely employed in cancer research to study signaling pathways, chemoresistance, and apoptosis, providing a robust background for BAG5 functional interrogation.
BAG5 functions as a co-chaperone that inhibits the ATPase activity of Hsp70/Hsc70 chaperones, thereby modulating protein folding and client processing. Additionally, BAG5 suppresses parkin E3 ubiquitin ligase activity, impairing parkin-mediated mitophagy and affecting mitochondrial quality control. Through these interactions, BAG5 influences proteasomal degradation, autophagy initiation, and apoptotic signaling. Key molecular partners include Hsp70, Hsc70, and parkin, and its activity is regulated by HSF1 and cellular stress signals such as oxidative and ER stress.
In the colorectal cancer context, BAG5 dysregulation may contribute to apoptotic resistance and altered proteostasis, potentially impacting tumor progression and chemotherapeutic response. The LoVo polyclonal knockout cells enable dissection of BAG5??s tumorigenic functions, including its crosstalk with the ubiquitin-proteasome system and autophagy pathways. Moreover, given BAG5??s inhibitory role on parkin, this model supports investigations bridging cancer biology and neurodegenerative disease mechanisms, where impaired mitophagy is a shared feature.
These polyclonal knockout cells are suitable for diverse experimental applications, such as assessing chaperone-mediated protein quality control using co-immunoprecipitation of BAG5-Hsp70 complexes, quantifying autophagy flux via LC3 and p62 immunoblotting, and measuring proteasome activity. The model further enables apoptosis profiling through caspase activation assays and Annexin V staining, as well as mitochondrial membrane potential analyses. Researchers can employ RT-qPCR for BAG5 mRNA validation and parkin auto-ubiquitination assays to probe E3 ligase function. For more information or technical support, please contact Ascent Research.
